Elevance Health, Inc. (NYSE:ELV) Shares Purchased by Marcum Wealth LLC

Marcum Wealth LLC boosted its position in Elevance Health, Inc. (NYSE:ELV) by 6.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 555 shares of the company’s stock after acquiring an additional 35 shares during the period. Marcum Wealth LLC’s holdings in Elevance Health were worth $288,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Paralel Advisors LLC lifted its holdings in shares of Elevance Health by 1.1% during the 3rd quarter. Paralel Advisors LLC now owns 4,160 shares of the company’s stock valued at $1,811,000 after acquiring an additional 47 shares in the last quarter. Dark Forest Capital Management LP grew its position in shares of Elevance Health by 114.9% during the 3rd quarter. Dark Forest Capital Management LP now owns 3,945 shares of the company’s stock valued at $1,718,000 after buying an additional 2,109 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its position in shares of Elevance Health by 7.3% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 1,469 shares of the company’s stock valued at $640,000 after buying an additional 100 shares during the last quarter. Northern Trust Corp grew its position in Elevance Health by 2.4% in the 3rd quarter. Northern Trust Corp now owns 2,416,459 shares of the company’s stock worth $1,052,175,000 after purchasing an additional 57,098 shares during the last quarter. Finally, Gallacher Capital Management LLC bought a new position in Elevance Health in the 3rd quarter worth about $214,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Trading Down 0.1 %

Shares of ELV stock opened at $534.42 on Friday. The firm has a market capitalization of $124.21 billion, a P/E ratio of 20.20, a price-to-earnings-growth ratio of 1.18 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.54. The firm’s fifty day simple moving average is $532.04 and its 200 day simple moving average is $506.77. Elevance Health, Inc. has a 1 year low of $412.00 and a 1 year high of $550.34.

Elevance Health (NYSE:ELV) last issued its earnings results on Thursday, April 18th. The company reported $10.64 EPS for the quarter, beating the consensus estimate of $10.54 by $0.10. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. The company had revenue of $42.27 billion for the quarter, compared to the consensus estimate of $42.49 billion. During the same quarter in the previous year, the company earned $9.46 EPS. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. As a group, sell-side analysts predict that Elevance Health, Inc. will post 37.2 EPS for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Investors of record on Monday, June 10th will be given a dividend of $1.63 per share. The ex-dividend date is Monday, June 10th. This represents a $6.52 annualized dividend and a yield of 1.22%. Elevance Health’s dividend payout ratio (DPR) is 24.64%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ELV. Jefferies Financial Group increased their price objective on shares of Elevance Health from $602.00 to $604.00 and gave the company a “buy” rating in a report on Friday, April 19th. StockNews.com downgraded shares of Elevance Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 6th. Baird R W upgraded shares of Elevance Health to a “strong-buy” rating in a research note on Thursday, May 30th. Robert W. Baird initiated coverage on shares of Elevance Health in a research note on Thursday, May 30th. They set an “outperform” rating and a $649.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their target price on Elevance Health from $628.00 to $631.00 and gave the stock an “overweight” rating in a report on Thursday, May 30th. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $607.36.

Insiders Place Their Bets

In other Elevance Health news, EVP Felicia F. Norwood sold 14,111 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $533.74, for a total transaction of $7,531,605.14. Following the completion of the sale, the executive vice president now directly owns 31,460 shares of the company’s stock, valued at approximately $16,791,460.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.35% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.